A Two-Arm, Multi-Center Trial of Revlimid and Rituximab, for First-Line Treatment in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL).

Trial Profile

A Two-Arm, Multi-Center Trial of Revlimid and Rituximab, for First-Line Treatment in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lenalidomide; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Dec 2011 Results were presented at the 53rd Annual Meeting of the American Society of Hematology (ASH)
    • 13 Dec 2011 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top